



Ontario

Cancer Care Ontario

Action Cancer Ontario



Cancer Risk Factors in Ontario

References

REFERENCES

1. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100E. A review of human carcinogens. Part E: Personal habits and indoor combustions. Lyon: International Agency for Research on Cancer; 2012.
2. U.S. Department of Health and Human Services. The health consequences of smoking: A report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
3. California Environmental Protection Agency. Proposed identification of environmental tobacco smoke as a toxic air contaminant. Part B: Health effects [Internet]. [updated 2005; cited 2011 Aug 29]. Available from: <http://www.arb.ca.gov/regact/ets2006/app3partb.pdf>.
4. Collishaw NE, Boyd NF, Cantor KF, Hammond SK, Johnson KC, Millar J. Canadian Expert Panel on tobacco smoke and breast cancer risk. Toronto: Ontario Tobacco Research Unit, OTRU Special Report Series; 2009.
5. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. *Int J Cancer* 2008;122(1):155-64.
6. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 83. Tobacco smoke and involuntary smoking. Lyon: International Agency for Research on Cancer; 2004.
7. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA* 2008;300(23):2765-78.
8. Tsui KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. *Clin Gastroenterol Hepatol* 2009;7(6):682-8.
9. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. *Int J Cancer* 2009;124(10):2406-15.
10. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. *Int J Cancer* 2009;125(1):171-80.
11. Bosetti C, Gallus S, Peto R, Negri E, Talamini R, Tavani A, et al. Tobacco smoking, smoking cessation, and cumulative risk of upper aerodigestive tract cancers. *Am J Epidemiol* 2008;167(4):468-73.
12. Bosetti C, Gallus S, Garavello W, La VC. Smoking cessation and the risk of oesophageal cancer: An overview of published studies. *Oral Oncol* 2006;42(10):957-64.
13. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev* 2009;18(2):541-50.
14. Committee on the Biological Effects of Ionizing Radiation. Health Effects of Exposure to Radon: BEIR VI. Washington DC: National Academy Press; 1999.
15. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, Boffetta P. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2010;19(5):1261-8.
16. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. *Int J Epidemiol* 2007;36(5):1048-59.
17. Stayner L, Bena J, Sasco AJ, Smith R, Steenland K, Kreuzer M, et al. Lung cancer risk and workplace exposure to environmental tobacco smoke. *Am J Public Health* 2007;97(3):545-51.
18. Lee YC, Boffetta P, Sturgis EM, Wei Q, Zhang ZF, Muscat J, et al. Involuntary smoking and head and neck cancer risk: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev* 2008;17(8):1974-81.
19. Pang D, McNally R, Birch JM. Parental smoking and childhood cancer: results from the United Kingdom Childhood Cancer Study. *Br J Cancer* 2003;88(3):373-81.
20. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. *Lancet Oncol* 2008;9(7):667-75.
21. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. *BMC Med* 2009;7:36.
22. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 89. Smokeless tobacco and some tobacco-specific N-nitrosamines. Lyon: International Agency for Research on Cancer; 2007.
23. U.S. Department of Health and Human Services. How tobacco causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
24. World Cancer Research Fund/ American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
25. World Health Organization. International guide for monitoring alcohol consumption and related harm. Geneva: World Health Organization; 2000.
26. Butt P, Beirness D, Cesa F, Gliksman L, Paradis C, Stockwell T. Alcohol and health in Canada: A summary of evidence and guidelines for low-risk drinking. Ottawa, ON: Canadian Centre on Substance Abuse; 2011.
27. Bagnardi V, Blangiardo M, La VC, Corrao G. A meta-analysis of alcohol drinking and cancer risk. *Br J Cancer* 2001;85(11):1700-5.
28. Corrao G, Bagnardi V, Zambon A, La VC. A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev Med* 2004;38(5):613-9.

29. Tramacere I, Negri E, Bagnardi V, Garavello W, Rota M, Scotti L, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers. Part 1: overall results and dose-risk relation. *Oral Oncol* 2010;46(7):497-503.
30. Islami F, Tramacere I, Rota M, Bagnardi V, Fedirko V, Scotti L, et al. Alcohol drinking and laryngeal cancer: overall and dose-risk relation--a systematic review and meta-analysis. *Oral Oncol* 2010;46(11):802-10.
31. Islami F, Fedirko V, Tramacere I, Bagnardi V, Jenab M, Scotti L, et al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. *Int J Cancer* 2011;129(10):2473-84.
32. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr., et al. Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. *Br J Cancer* 2002;87(11):1234-45.
33. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. *Ann Intern Med* 2004;140(8):603-13.
34. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol* 2011;22(9):1958-72.
35. Key J, Hodgson S, Omar RZ, Jensen TK, Thompson SG, Boobis AR, et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *Cancer Causes Control* 2006;17(6):759-70.
36. Druesne-Pecollo N, Tehard B, Mallet Y, Gerber M, Norat T, Hercberg S, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. *Lancet Oncol* 2009;10(2):173-80.
37. Boffetta P, Hashibe M. Alcohol and cancer. *Lancet Oncol* 2006;7(2):149-56.
38. World Cancer Research Fund/ American Institute for Cancer Research. Continuous update project. Colorectal cancer report 2010 summary. Food, nutrition, physical activity, and the prevention of cancer [Internet]. AICR; 2011 [cited 2012 Mar 8]. Available from: http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/CUP_CRC_summary_2011.pdf.
39. Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. *PLoS One* 2011;6(6):e20456.
40. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. *Gastric Cancer* 2007;10(2):75-83.
41. Wang XQ, Terry PD, Yan H. Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. *World J Gastroenterol* 2009;15(18):2204-13.
42. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology* 2010;138(6):2029-43.
43. Freedman ND, Park Y, Subar AF, Hollenbeck AR, Leitzmann MF, Schatzkin A, et al. Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. *Int J Cancer* 2008;122(10):2330-6.
44. Boeing H, Dietrich T, Hoffmann K, Pischon T, Ferrari P, Lahmann PH, et al. Intake of fruits and vegetables and risk of cancer of the upper aerodigestive tract: the prospective EPIC-study. *Cancer Causes Control* 2006;17(7):957-69.
45. Key TJ. Fruit and vegetables and cancer risk. *Br J Cancer* 2011;104(1):6-11.
46. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO obesity technical report summary. Geneva: World Health Organization; 2000.
47. World Cancer Research Fund/ American Institute for Cancer Research. Continuous update project report summary. Food, nutrition, physical activity, and the prevention of breast cancer [Internet]. AICR; 2010 [cited 2012 Jun 19]. Available from: http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/cu_breast_cancer_report_2008_summary.pdf.
48. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M, Renehan AG, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008;371(9612):569-78.
49. Harriss DJ, Atkinson G, George K, Cable NT, Reilly T, Haboubi N, et al. Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. *Colorectal Dis* 2009;11(6):547-63.
50. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A, Suzuki R, et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. *Int J Cancer* 2009;124(3):698-712.
51. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst* 2011;103(3):250-63.
52. Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. *Am J Epidemiol* 2011;174(6):661-71.
53. Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. *Breast Cancer Res* 2012;14(3):R76.
54. Mathew A, George PS, Ildaphonse G, Mathew A, George PS, Ildaphonse G. Obesity and kidney cancer risk in women: a meta-analysis (1992-2008). *Asian Pac J Cancer Prev* 2009;10(3):471-8.
55. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG, Crosbie EJ, et al. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2010;19(12):3119-30.
56. Lynch BM. Sedentary behavior and cancer: a systematic review of the literature and proposed biological mechanisms. *Cancer Epidemiol Biomarkers Prev* 2010;19(11):2691-709.
57. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. *Eur J Cancer* 2010;46(14):2593-604.
58. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. *Br J Cancer* 2009;100(4):611-6.
59. Harriss DJ, Atkinson G, Batterham A, George K, Cable NT, Reilly T, et al. Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. *Colorectal Dis* 2009;11(7):689-701.

60. Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. *Br J Sports Med* 2008;42(8):636-47.
61. Voskuil DW, Monninkhof EM, Elias SG, Vlems FA, van Leeuwen FE. Physical activity and endometrial cancer risk, a systematic review of current evidence. *Cancer Epidemiol Biomarkers Prev* 2007;16(4):639-48.
62. Cust AE, Armstrong BK, Friedenreich CM, Slimani N, Bauman A. Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. *Cancer Causes Control* 2007;18(3):243-58.
63. Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. *Br J Cancer* 2010;103(7):933-8.
64. Schottenfeld D and Fraumeni JF, editors. *Cancer Epidemiology and Prevention*. 3rd ed. New York: Oxford University Press; 2006
65. Parkin DM. 15. Cancers attributable to reproductive factors in the UK in 2010. *Br J Cancer* 2011;105(Suppl 2):S73-S76.
66. Reeves GK, Pirie K, Green J, Bull D, Beral V. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. *Br J Cancer* 2009;100(3):538-44.
67. Li CI, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Liff JM, et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15(5):946-54.
68. Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M. Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. *Int J Cancer* 1999;81(1):49-55.
69. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. *Cancer Epidemiol Biomarkers Prev* 2003;12(10):1053-60.
70. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjønneland A, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2010;127(2):442-51.
71. Karageorgi S, Hankinson SE, Kraft P, De V, I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. *Int J Cancer* 2010;126(1):208-16.
72. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer* 2011;105(9):1436-42.
73. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. *Int J Cancer* 2006;119(5):1108-24.
74. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. *Cancer Epidemiol Biomarkers Prev* 2004;13(10):1558-68.
75. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. *Int J Cancer* 2012;131(4):938-48.
76. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. Breastfeeding and risk of ovarian cancer in two prospective cohorts. *Cancer Causes Control* 2007;18(5):517-23.
77. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. *Lancet* 1997;350(9084):1047-59.
78. Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. *Am J Epidemiol* 2010;172(10):1181-9.
79. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 91. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. Lyon: International Agency for Research on Cancer; 2007.
80. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100A. A review of human carcinogens. Part A: Pharmaceuticals. Lyon: International Agency for Research on Cancer; 2012.
81. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet* 1996;347(9017):1713-27.
82. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. *Int J Cancer* 2007;120(4):885-91.
83. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. *J Hepatol* 2007;47(4):506-13.
84. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet* 2008;371(9609):303-14.
85. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. *Lancet Oncol* 2006;7(11):910-8.
86. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003;362(9382):419-27.
87. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2011;128(1):144-56.
88. Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. *Am J Epidemiol* 2010;172(12):1394-403.
89. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. *Oncogene* 2004;23(38):6379-91.
90. Wiseman RA. Breast cancer: critical data analysis concludes that estrogens are not the cause, however lifestyle changes can alter risk rapidly. *J Clin Epidemiol* 2004;57(8):766-72.
91. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100D. A review of human carcinogens. Part D: Radiation. Lyon: International Agency for Research on Cancer; 2012.

92. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. *Int J Cancer* 1997;73(2):198-203.
93. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. *Eur J Cancer* 2005;41(1):45-60.
94. Armstrong BK, Krickler A. The epidemiology of UV induced skin cancer. *J Photochem Photobiol B* 2001;63(1-3):8-18.
95. Caini S, Gandini S, Sera F, Raimondi S, Fargnoli MC, Boniol M, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. *Eur J Cancer* 2009;45(17):3054-63.
96. Chang YM, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman W, et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. *Int J Epidemiol* 2009;38(3):814-30.
97. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. *Cancer Causes Control* 2001;12(1):69-82.
98. Cust AE, Jenkins MA, Goumas C, Armstrong BK, Schmid H, Aitken JF, et al. Early-life sun exposure and risk of melanoma before age 40 years. *Cancer Causes Control* 2011;22(6):885-97.
99. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. *J Natl Cancer Inst Monogr* 2008;(38):1-93.
100. The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. *Int J Cancer* 2007;120(5):1116-22.
101. Hirst N, Gordon L, Gies P, Green AC. Estimation of avoidable skin cancers and cost-savings to government associated with regulation of the solarium industry in Australia. *Health Policy* 2009;89(3):303-11.
102. Lazovich D, Vogel RI, Berwick M, Weinstock MA, Anderson KE, Warshaw EM. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. *Cancer Epidemiol Biomarkers Prev* 2010;19(6):1557-68.
103. Cust AE, Armstrong BK, Goumas C, Jenkins MA, Schmid H, Hopper JL, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. *Int J Cancer* 2011;128(10):2425-35.
104. Veierod MB, Adami HO, Lund E, Armstrong BK, Weiderpass E. Sun and solarium exposure and melanoma risk: effects of age, pigmented characteristics, and nevi. *Cancer Epidemiol Biomarkers Prev* 2010;19(1):111-20.
105. Vajdic CM, Krickler A, Giblin M, McKenzie J, Aitken JF, Giles GG, et al. Artificial ultraviolet radiation and ocular melanoma in Australia. *Int J Cancer* 2004;112(5):896-900.
106. Schmidt-Pokrzywniak A, Jockel KH, Bornfeld N, Sauerwein W, Stang A. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Artificial ultraviolet radiation and ocular melanoma in Australia. *Ophthalmology* 2009;116(2):340-8.
107. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. Special Report: Policy: A review of human carcinogens --Part D: radiation. *The Lancet Oncology* 2009;10(8)
108. National Toxicology Program. Report on Carcinogens. Research Triangle Park (NC): US Department of Health and Human Services, Public Health Service, National Toxicology Program; 2011.
109. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Man-made Minerals Fibres and Radon, Vol 43. Lyon, France: IARC; 1988.
110. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 75. Ionizing radiation, part 1: X- and gamma-radiation, and neutrons. Lyon: International Agency for Research on Cancer; 2000.
111. Lubin JH, Boice JD, Jr., Edling C, Hornung RW, Howe GR, Kunz E, et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. *J Natl Cancer Inst* 1995;87(11):817-27.
112. Krewski D, Lubin JH, Zielinski JM, Alavanja M, Catalan VS, Field RW, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. *Epidemiology* 2005;16(2):137-45.
113. Krewski D, Lubin JH, Zielinski JM, Alavanja M, Catalan VS, Field RW, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. *J Toxicol Environ Health A* 2006;69(7):533-97.
114. Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ* 2005;330(7485):223.
115. Darby S, Hill D, Deo H, Auvinen A, Barros-Dios JM, Baysson H, et al. Residential radon and lung cancer--detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. *Scand J Work Environ Health* 2006;32 Suppl 1:1-83.
116. Lubin JH, Wang ZY, Boice JD, Jr., Xu ZY, Blot WJ, De Wang L, et al. Risk of lung cancer and residential radon in China: pooled results of two studies. *Int J Cancer* 2004;109(1):132-7.
117. United Nations Scientific Committee on the Effects of Atomic Radiation. Effects of Ionizing Radiation. Volume 1: Report to the General Assembly, Annex A: Epidemiological Studies of Radiation and Cancer. New York: United Nations; 2006.
118. Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S, Funamoto S, et al. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. *Radiat Res* 2004;162(4):377-89
119. Land CE, Saku T, Hayashi Y, Takahara O, Matsuura H, Tokuoka S, et al. Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk. *Radiat Res* 1996;146(1):28-36.
120. Schneider AB, Lubin J, Ron E, Abrahams C, Stovall M, Goel A, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. *Radiat Res* 1998;149(6):625-30.
121. Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C, et al. The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: estimates of radiation-related cancer risks. *Radiat Res* 2007;167(4):396-416.

122. Sont WN, Zielinski JM, Ashmore JP, Jiang H, Krewski D, Fair ME, et al. First analysis of cancer incidence and occupational radiation exposure based on the National Dose Registry of Canada. *Am J Epidemiol* 2001;153(4):309-18.
123. Institute of Medicine of the National Academy of Science. *Asbestos: Selected Cancers*. Washington, DC: National Academies Press; 2006.
124. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100C. A review of human carcinogens. Part C: Arsenic, metals, fibres, and dusts. Lyon: International Agency for research on Cancer; 2012.
125. Payne JJ, Pichora E. Filing for workers' compensation among Ontario cases of mesothelioma. *Can Respir J* 2009;16(5):148-52.
126. Lenters V, Vermeulen R, Dogger S, Stayner L, Portengen L, Burdorf A, et al. A meta-analysis of asbestos and lung cancer: Is better quality exposure assessment associated with steeper slopes of the exposure-response relationships? *Environ Health Perspect* 2011;119(11):1547-55.
127. Anderson HA, Lillis R, Daum SM, Fischbein AS, Selikoff IJ. Household-contact asbestos neoplastic risk. *Ann N Y Acad Sci* 1976;271(1):311-23.
128. Ferrante D, Bertolotti M, Todesco A, et al. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. *Environ Health Perspect* 2007;115(10):1401-5.
129. Reid A, Heyworth J, de Klerk N, Musk AW. The mortality of women exposed environmentally and domestically to blue asbestos at Wittenoom, Western Australia. *Occup Environ Med* 2008;65(11):743-9.
130. Reid A, Segal A, Heyworth JS, et al. Gynecologic and breast cancers in women after exposure to blue asbestos at Wittenoom. *Cancer Epidemiol Biomarkers Prev* 2009;18(1):140-7.
131. Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, et al. Occupational Exposure to Asbestos and Ovarian Cancer: A Meta-analysis. *Environ Health Perspect* 2011;119(9):1211-7.
132. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. Special Report: Policy: A review of human carcinogens—Part C: metals, arsenic, dusts, and fibres. *The Lancet Oncology* 2009;10(5):453-4.
133. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. *Proc Natl Acad Sci USA* 2010;107(28):1261-6.
134. Pelucchi C, Pira E, Piolatto G, et al. Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996–2005. *Ann Oncol* 2006;17(7):1039-50.
135. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 62. Wood dust and formaldehyde. Lyon: International Agency for Research on Cancer; 1995.
136. Demers PA, Kogevinas M, Boffetta P, Leclerc A, Luce D, Gérin M, et al. Wood dust and sino-nasal cancer: Pooled reanalysis of twelve case-control studies. *Am J Ind Med* 1995;28(2):151-66.
137. Baris I, Artvinli M, Saracci R, Simonato L, Pooley F, Skidmore J, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: A four-year study in the cappadocian region of turkey. *Int J Cancer* 1987;39(1):10-7.
138. Baris YI, Grandjean P. Prospective Study of Mesothelioma Mortality in Turkish Villages With Exposure to Fibrous Zeolite. *J Natl Cancer Inst* 2006;98(6):414-7.
139. Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. *Am J Epidemiol* 2001;153(6):559-64.
140. Mink PJ, Alexander DD, Barraji LM, Kelsh MA, Tsuji JS. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. *Regul Toxicol Pharmacol* 2008;52(3):299-310.
141. Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. *Am J Epidemiol* 1995;141(6):523-30.
142. Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney J, et al. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. *Cancer Causes Control* 2004;15(5):465-72.
143. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for nickel. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2005.
144. Report of the International Committee on Nickel Carcinogenesis in Man. *Scandinavian journal of work, environment & health* 1990;16(1 Spec No)
145. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for beryllium. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2002.
146. Kreiss K, Day GA, Schuler CR. Beryllium: a modern industrial hazard. *Annu Rev Public Health* 2007;28:259-77.
147. Sanderson WT, Ward EM, Steenland K, Petersen MR. Lung cancer case-control study of beryllium workers. *Am J Ind Med* 2001;39(2):133-44.
148. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for cadmium. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2012.
149. Stayner L, Smith R, Thun M, Schnorr T, Lemen R. A dose-response analysis and quantitative assessment of lung cancer risk and occupational cadmium exposure. *Ann Epidemiol* 1992;2(3):177-94.
150. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for chromium. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2012.
151. Cole P, Rodu B. Epidemiologic studies of chrome and cancer mortality: a series of meta-analyses. *Regul Toxicol Pharmacol* 2005;43(3):225-31.
152. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100F. A review of human carcinogens. Part F: Chemical agents and related occupations. Lyon: International Agency for Research on Cancer; 2012.
153. Soskolne CL, Jhangri GS, Siemiatycki J, Lakhani R, Dewar R, Burch JD, et al. Occupational exposure to sulfuric acid in southern Ontario, Canada, in association with laryngeal cancer. *Scand J Work Environ Health* 1992;18(4):225-32.
154. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Benzene. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2007.
155. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. *Environ Health* 2010;9:31. doi: 110.1186/1476-069X-9-31. PubMed PMID: 20584305; PubMed Central PMCID: PMC2903550.

156. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for 1,3-butadiene. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2012.
157. Delzell E, Sathikumar N, Graff J, Macaluso M, Maldonado G, Matthews R. An updated study of mortality among North American synthetic rubber industry workers. *Res Rep Health Eff Inst* 2006;(132):1-63.
158. Whitworth KW, Symanski E, Coker AL. Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995-2004. *Environ Health Perspect* 2008;116(11):1576-80.
159. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risk to humans: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol, Vol 88. Lyon (France): IARC; 2006.
160. Bachand AM, Mundt KA, Mundt DJ, Montgomery RR. Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer: a meta-analysis. *Crit Rev Toxicol* 2010;40(2):85-100.
161. Zhang L, Steinmaus C, Eastmond DA, Xin XK, Smith MT. Formaldehyde exposure and leukemia: a new meta-analysis and potential mechanisms. *Mutat Res* 2009;681(2-3):150-68.
162. Bosetti C, McLaughlin JK, Tarone RE, Pira E, La Vecchia C. Formaldehyde and cancer risk: a quantitative review of cohort studies through 2006. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2008;19(1):29-43.
163. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality from solid cancers among workers in formaldehyde industries. *Am J Epidemiol* 2004;159(12):1117-30.
164. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 33. Polynuclear aromatic hydrocarbons, part 2, carbon blacks, mineral oils (lubricant base oils and derived products) and some nitroarenes. Lyon: International Agency for Research on Cancer; 1984.
165. Costello S, Friesen MC, Christiani DC, Eisen EA. Metalworking fluids and malignant melanoma in autoworkers. *Epidemiology* 2011;22(1):90-7.
166. Benbrahim-Tallaa L, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of diesel-engine and gasoline-engine exhausts and some nitroarenes. *Lancet Oncol* 2012;13(7):663-4.
167. Pronk A, Coble J, Stewart PA. Occupational exposure to diesel engine exhaust: a literature review. *J Expo Sci Environ Epidemiol* 2009;19(5):443-57.
168. Rushton L. The problem with Diesel. *J Natl Cancer Inst* 2012;104(11):796-7.
169. Attfield MD, Schleiff PL, Lubin JH, Blair A, Stewart PA, Vermeulen R, et al. The Diesel Exhaust in Miners study: a cohort mortality study with emphasis on lung cancer. *J Natl Cancer Inst* 2012;104(11):869-83.
170. Silverman DT, Samanic CM, Lubin JH, Blair AE, Stewart PA, Vermeulen R, et al. The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. *J Natl Cancer Inst* 2012;104(11):855-68.
171. Garshick E, Laden F, Hart JE, Davis ME, Eisen EA, Smith TJ. Lung Cancer and Elemental Carbon Exposure in Trucking Industry Workers. *Environ Health Perspect* 2012;120(9):1301-6.
172. Laden F, Hart JE, Eschenroeder A, Smith TJ, Garshick E. Historical estimation of diesel exhaust exposure in a cohort study of U.S. railroad workers and lung cancer. *Cancer Causes Control* 2006;17(7):911-9.
173. Olsson AC, Gustavsson P, Kromhout H, Peters S, Vermeulen R, Bruske I, et al. Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. *Am J Respir Crit Care Med* 2011;183(7):941-8.
174. Pintos J, Parent ME, Richardson L, Siemiatycki J. Occupational exposure to diesel engine emissions and risk of lung cancer: evidence from two case-control studies in Montreal, Canada. *Occup Environ Med* 2012;69(11):787-92.
175. Boffetta P, Silverman DT. A meta-analysis of bladder cancer and diesel exhaust exposure. *Epidemiology* 2001;12(1):125-30.
176. Emmelin A, Nystrom L, Wall S. Diesel exhaust exposure and smoking: a case-referent study of lung cancer among Swedish dock workers. *Epidemiology* 1993;4(3):237-44.
177. Ris C. U.S. EPA health assessment for diesel engine exhaust: a review. *Inhal Toxicol* 2007;19 Suppl 1:229-39.
178. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for polycyclic aromatic hydrocarbons (PAHs). Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 1995.
179. Betts WD. Tar and pitch. New York: John Wiley & Sons; 1997.
180. Partanen T, Boffetta P. Cancer risk in asphalt workers and roofers: review and meta-analysis of epidemiologic studies. *Am J Ind Med* 1994;26(6):721-40.
181. Evanoff BA, Gustavsson P, Hogstedt C. Mortality and incidence of cancer in a cohort of Swedish chimney sweeps: an extended follow up study. *Br J Ind Med* 1993;50(5):450-9.
182. Spinelli JJ, Demers PA, Le ND, Friesen MD, Lorenzi MF, Fang R, et al. Cancer risk in aluminum reduction plant workers (Canada). *Cancer Causes Control* 2006;17(7):939-48.
183. Friesen MC, Demers PA, Spinelli JJ, Lorenzi MF, Le ND. Comparison of two indices of exposure to polycyclic aromatic hydrocarbons in a retrospective aluminium smelter cohort. *Occup Environ Med* 2007;64(4):273-8.
184. Ontario Ministry of the Environment. Air Quality in Ontario: Report for 2010 [Internet]. Toronto: Queen's Printer for Ontario; 2012 [cited 2012 Aug 29]. Available from: http://www.ene.gov.on.ca/stdprodconsume/groups/ltr/ene/@resources/documents/resource/stdprod_095558.pdf.
185. Chen H, Goldberg MS, Villeneuve PJ. A systematic review of the relation between long-term exposure to ambient air pollution and chronic diseases. *Rev Environ Health* 2008;23(4):243-97.
186. Turner MC, Krewski D, Pope CA3, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. *Am J Respir Crit Care Med* 2011;184(12):1374-81.
187. Lepeule J, Laden F, Dockery D, Schwartz J. Chronic Exposure to Fine Particles and Mortality: An Extended Follow-up of the Harvard Six Cities Study from 1974 to 2009. *Environ Health Perspect* 2012;120(7):965-70.
188. Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. *Br Med Bull* 2003;68:71-94.

189. Valavanidis A, Fiotakis K, Vlachogianni T. Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 2008;26(4):339-62.
190. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100B. A review of human carcinogens. Part B: Biological agents. Lyon: International Agency for Research on Cancer; 2012.
191. Weiss LM. Epstein-Barr virus and Hodgkin's disease. *Curr Oncol Rep* 2000;2(2):199-204.
192. Carpenter LM, Newton R, Casabonne D, Ziegler J, Mbulaitaye S, Mbidde E, et al. Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. *Int J Cancer* 2008;122(6):1319-23.
193. Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. *PLoS One* 2008;3(6):e2505.
194. Hsu JL, Glaser SL. Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. *Crit Rev Oncol Hematol* 2000;34(1):27-53.
195. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. *Int J Cancer* 1998;75(3):347-54.
196. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. *Br J Cancer* 2005;92(3):607-12.
197. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. *Int J Cancer* 2011;128(1):176-84.
198. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. *Cancer Sci* 2004;95(9):745-52.
199. Dal ML, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. *Cancer Epidemiol Biomarkers Prev* 2006;15(11):2078-85.
200. Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. *N Engl J Med* 1999;340(24):1863-71.
201. Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, et al. The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. *Int J Cancer* 2003;103(2):226-32.
202. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet* 2007;370(9581):59-67.
203. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. *J Natl Cancer Inst* 2007;99(12):962-72.
204. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer* 2008;123(1):187-94.
205. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst* 2011;103(9):753-62.
206. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. *Blood* 2006;108(12):3786-91.
207. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999;189(1):12-9.
208. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. *Int J Cancer* 2011;128(4):927-35.
209. De VH, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 2009;124(7):1626-36.
210. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de SS. Human papillomavirus prevalence and type distribution in penile carcinoma. *J Clin Pathol* 2009;62(10):870-8.
211. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. *Cancer Causes Control* 2009;20(4):449-57.
212. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2005;14(2):467-75.
213. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between *Helicobacter pylori* seropositivity and gastric cancer. *Gastroenterology* 1998;114(6):1169-79.
214. Helicobacter and Cancer Collaborative Group. Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts. *Gut* 2001;49(3):347-53.
215. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between *cagA* seropositivity and gastric cancer. *Gastroenterology* 2003;125(6):1636-44.
216. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 1994;330(18):1267-71.
217. Wroblewski LE, Peek RM, Jr., Wilson KT. *Helicobacter pylori* and gastric cancer: factors that modulate disease risk. *Clin Microbiol Rev* 2010;23(4):713-39.
218. Bedwani R, Renganathan E, El KF, Braga C, Abu Seif HH, Abul AT, et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. *Br J Cancer* 1998;77(7):1186-9.
219. Weber W, Estoppey J, Stoll H. Familial cancer diagnosis. *Anticancer Res* 2001;21(5):3631-5.

220. Petrucelli, N, Daly, M. B., and Feldman, G. L. BRCA1 and BRCA2 hereditary breast and ovarian cancer [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1998 [updated 2011 Jan 20; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1247/>.
221. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72(5):1117-30.
222. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007;25(11):1329-33.
223. Garber JE, Offit K. Hereditary cancer predisposition syndromes. *J Clin Oncol* 2005;23(2):276-92.
224. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. *Eur J Cancer* 2010;46(12):2275-84.
225. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. *Br J Cancer* 2007;96(1):11-5
226. Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. *Am J Hum Genet* 1992;51(2):344-56.
227. Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. *Cancer Res* 2006;66(16):8287-92.
228. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18(2):400-7.
229. Kohlmann, W. and Gruber, S. B. Lynch syndrome [Internet]. In: Pagon, R. A., Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 2004 [updated 2012 Sep 20; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1211/>.
230. Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. *Cancer J* 2011;17(6):405-15.
231. Jaspersion, K. W. and Burt, R. W. APC-associated polyposis conditions [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1998 [updated 2011 Oct 27; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1345/>.
232. Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. *Cancer Epidemiol Biomarkers Prev* 2006;15(2):312-4.
233. Amos, C. I., Frazier, M. L., Wei, C., and McGarrity, T. J. Peutz-Jeghers syndrome [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 2001 [updated 2011 Feb 22; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1266/>.
234. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. *Am J Gastroenterol* 2010;105(6):1258-64.
235. Stanford JL, Ostrander EA. Familial prostate cancer. *Epidemiol Rev* 2001;23(1):19-23.
236. Schaid DJ. The complex genetic epidemiology of prostate cancer. *Hum Mol Genet* 2004;13 Spec No 1:R103-R121.
237. Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, Koivisto PA, Tammela TL, Deshmukh S, et al. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. *Hum Genet* 2007;121(2):257-67.
238. Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. *Am J Hum Genet* 2001;68(5):1207-18.
239. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. *Nat Genet* 2002;30(2):181-4
240. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. *Am J Hum Genet* 2002;70(5):1299-304.
241. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. *Nat Genet* 2002;32(2):321-5.
242. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Chang B, et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. *Am J Hum Genet* 2003;72(1):208-12.
243. Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. *Blood Cells Mol Dis* 2004;32(1):246-61.
244. Gatti, R. Ataxia-Telangiectasia [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1999 [updated 2010 Mar 11; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK26468/>.
245. Alter, B. P. Fanconi Anemia [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 2002 [updated 2012 Sep 6; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1401/>.
246. Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. *Cancer Genet* 2011;204(5):227-44.
247. Fong CT, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. *Cancer Genet Cytogenet* 1987;28(1):55-76.
248. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. *Lancet* 2000;355(9199):165-9.
249. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. *Oncologist* 2009;14(2):164-73.
250. Lohmann, D. R. and Gallie, B. L. Retinoblastoma [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 2000 [updated 2010 Jun 10; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1452/>.
251. D'Orazio JA. Inherited cancer syndromes in children and young adults. *J Pediatr Hematol Oncol* 2010;32(3):195-228.
252. Dome, J. S. and Huff, V. Wilms tumor [Internet]. In: Pagon, R. A, Bird, T. D., Dolan, C. R., et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 2003 [updated 2011 Jun 14; cited 2012 Oct 1]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1294/>.

253. Ruteshouser EC, Huff V. Familial Wilms tumor. *Am J Med Genet C Semin Med Genet* 2004;129C(1):29-34.
254. Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. *Am J Gastroenterol* 2010;105(7):1480-7.
255. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI, Jess T, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. *Am J Gastroenterol* 2005;100(12):2724-9.
256. Canavan C, Abrams KR, Mayberry J, Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. *Aliment Pharmacol Ther* 2006;23(8):1097-104.
257. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP, et al. The risk of cancer in patients with Crohn's disease. *Dis Colon Rectum* 2007;50(6):839-55.
258. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol* 2012;10(6):639-45.
259. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Autoimmune disease and subsequent digestive tract cancer by histology. *Ann Oncol* 2012;23(4):927-33.
260. Guagnozzi D, Lucendo AJ. Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? *World J Gastrointest Endosc* 2012;4(4):108-16.
261. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update. *J Intern Med* 2008;264(6):514-27.
262. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. *CA Cancer J Clin* 2010;60(4):207-21.
263. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. *Endocr Relat Cancer* 2009;16(4):1103-23.
264. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol* 2006;4(3):369-80.
265. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. *Int J Cancer* 2012;130(7):1639-48.
266. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. *Diabetes Metab Res Rev* 2012;28(2):109-22.
267. Yang WS, Va P, Bray F, Gao S, Gao J, Li HL, et al. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. *PLoS One* 2011;6(12):e27326.
268. Huxley R, Ansary-Moghaddam A, Berrington de GA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer* 2005;92(11):2076-83.
269. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. *Eur J Cancer* 2011;47(13):1928-37.
270. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. *J Natl Cancer Inst* 2005;97(22):1679-87.
271. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *Am J Gastroenterol* 2011;106(11):1911-21.
272. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. *Eur J Epidemiol* 2011;26(11):863-76.
273. Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. *Dig Dis Sci* 2012;57(6):1576-85.
274. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. *Diabetologia* 2006;49(12):2819-23.
275. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. *Int J Cancer* 2007;121(4):856-62.
276. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. *Asian Pac J Cancer Prev* 2011;12(4):1061-5.
277. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. *Arch Intern Med* 2004;164(14):1482-8.
278. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. *JAMA* 2002;287(15):1972-81.
279. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. *Nat Rev Cancer* 2003;3(9):676-84.
280. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. *Aliment Pharmacol Ther* 2010;32(10):1222-7.
281. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340(11):825-31.
282. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011;365(15):1375-83.
283. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: Cancer risk in Barrett's oesophagus. *Aliment Pharmacol Ther* 2007;26(11-12):1465-77.
284. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. *Am J Epidemiol* 2008;168(3):237-49.

285. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2010;8(3):235-44.
286. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. *Gut* 2012;61(7):970-6.
287. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. *J Natl Cancer Inst* 2011;103(13):1049-57.
288. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association technical review on the management of Barrett's esophagus. *Gastroenterology* 2011;140(3):e18-e52.
289. Wood HM, Elder JS. Cryptorchidism and testicular cancer: separating fact from fiction. *J Urol* 2009;181(2):452-61.
290. Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. *Am J Surg Pathol* 2003;27(6):836-41.
291. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. *N Engl J Med* 2005;353(3):229-37.
292. Shore RE. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. *Radiat Res* 1992;131(1):98-111.
293. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood* 2005;105(7):2664-70.
294. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet* 2007;370(9581):59-67.
295. Engels EA, Pfeiffer RM, Fraumeni JF, Jr., Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. *JAMA* 2011;306(17):1891-901.
296. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. *Nephrol Dial Transplant* 2007;22 Suppl 1:i4-10.
297. Bosetti C, Rosato V, Gallus S, Cuzick J, La VC. Aspirin and cancer risk: a quantitative review to 2011. *Ann Oncol* 2012;23(6):1403-15.
298. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet* 2010;376(9754):1741-50.
299. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet* 2007;369(9573):1603-13.
300. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. *Ann Intern Med* 1998;128(9):713-20.
301. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. *JAMA* 2005;294(1):47-55.